• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

Fidelity MoneyBuilder Balanced Fund Y-Accumulating

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider Fidelity
Fund Summary The Fund's investment objective is to achieve an attractive level of income together with some long term capital growth. The Fund will obtain exposure primarily to the UK. The Fund may invest directly in UK government and corporate bonds and other fixed interest securities, preference shares, convertibles and ordinary shares or may achieve exposure indirectly through the use of Derivatives. The Fund may also invest in other transferable securities, money market instruments, collective investment schemes, cash and near cash and deposits. Derivatives may be used for efficient portfolio management and investment purposes and may include (but are not limited to) Derivatives on exchange rates, interest rates, inflation and credit. The Fund may also take positions which enable it to benefit from falling asset prices.
Fund code YRMBA
Managers Michael Clark, Sajiv Vaid
Manager Tenure 10 years
Morningstar Category Currently unavailable
IMA Sector Mixed Investment 40-85% Shares
Fund Size £418 million
Fund Type OEIC
Management Style Active
Total Expense Ratio (TER) 0.67%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £0.5743
Buy Price £0.5743
Price Change -0.347%
Price Date 19th July 2019
Yield 3.44%
Dividend Frequency Yearly
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 11th November 2015
Fund Status OPEN
Michael Clark joined Fidelity International in 2002 as an Equity Research Analyst. From 2002 to 2007 he covered a variety of sectors including oil services, construction and housebuilding, automotive and mining. Michael became a Portfolio Manager in 2007. Prior to joining Fidelity, Michael was an equity analyst for JP Morgan, Enskilda and Morgan Grenfell. Through these positions, he covered the engineering, consumer goods, pharmaceuticals and industrial services sectors, and now has a total of 22 years experience. Michael holds an MA in Modern Languages from Cambridge University.

3-year Mean Monthly Return: 0.244%

Annual Returns 2018 2017 2016
Fund Performance +0.65% -0.72% +8.52%
Benchmark Performance
+0.64% +5.43% +14.50%
Time Period Cumulative Benchmark Performance
Fund Compared to Benchmark
1 day -0.35% -0.03% -0.32%
1 week -0.10% +1.54% -1.64%
1 month 0.95% +1.89% -0.94%
3 months 1.39% +3.85% -2.46%
6 months 6.25% +6.72% -0.46%
1 year 1.16% +1.01% +0.15%
3 years 6.55% +25.70% -19.15%
5 years Currently unavailable +35.01% Currently unavailable
10 years Currently unavailable +121.89% Currently unavailable
YTD 8.75% +9.60% -0.85%
Since inception 14.86% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
United Kingdom of Great Britain and Northern Ireland 1.75% GBR 9.32%
United Kingdom of Great Britain and Northern Ireland 4.25% GBR 4.21%
AstraZeneca PLC GBR 3.50%
BP PLC GBR 3.30%
GlaxoSmithKline PLC GBR 3.18%
Royal Dutch Shell PLC Class A GBR 3.04%
HSBC Holdings PLC GBR 2.85%
United Kingdom of Great Britain and Northern Ireland 4.5% GBR 2.74%
United Kingdom of Great Britain and Northern Ireland 3.25% GBR 2.74%
United Kingdom of Great Britain and Northern Ireland 5% GBR 2.65%
Dividend Date Per share amount Reinvestment Price
1st March 2019 0.0197 £0.5535
1st March 2018 0.0196 £0.5361
1st March 2017 0.0179 £0.5602
1st March 2016 0.0049 £0.5090